-DOCSTART- -X- O
Seasonal -X- _ B-Patient
influenza -X- _ I-Patient
can -X- _ O
be -X- _ O
a -X- _ O
self-limiting -X- _ O
illness -X- _ O
in -X- _ O
healthy -X- _ O
individuals -X- _ O
but -X- _ O
is -X- _ O
associated -X- _ O
with -X- _ O
short- -X- _ O
term -X- _ O
morbidity -X- _ O
and -X- _ O
economic -X- _ O
burden. -X- _ O
Influenza -X- _ O
can -X- _ O
cause -X- _ O
significant -X- _ O
morbidity -X- _ O
and -X- _ O
mortality -X- _ O
in -X- _ O
young -X- _ O
children -X- _ O
, -X- _ O
the -X- _ O
elderly -X- _ O
, -X- _ O
pregnant -X- _ O
and -X- _ O
post-partum -X- _ O
women -X- _ O
, -X- _ O
patients -X- _ O
with -X- _ O
co-morbidities -X- _ O
and -X- _ O
the -X- _ O
immunocompromised. -X- _ O
Neuraminidase -X- _ B-Intervention
inhibitors -X- _ I-Intervention
( -X- _ I-Intervention
NAIs -X- _ I-Intervention
) -X- _ I-Intervention
are -X- _ O
the -X- _ O
treatment -X- _ O
of -X- _ O
choice -X- _ O
for -X- _ O
influenza -X- _ O
due -X- _ O
to -X- _ O
widespread -X- _ O
resistance -X- _ O
to -X- _ O
the -X- _ O
adamantanes. -X- _ O
NAIs -X- _ O
are -X- _ O
efficacious -X- _ O
for -X- _ O
the -X- _ O
treatment -X- _ O
of -X- _ O
influenza -X- _ B-Patient
in -X- _ O
ambulatory -X- _ O
patients -X- _ O
with -X- _ O
mild -X- _ O
illness -X- _ O
, -X- _ O
when -X- _ O
initiated -X- _ O
within -X- _ O
48 -X- _ O
h -X- _ O
of -X- _ O
symptom -X- _ O
onset. -X- _ O
Early -X- _ B-Outcome
treatment -X- _ I-Outcome
with -X- _ I-Outcome
NAIs -X- _ I-Outcome
has -X- _ I-Outcome
been -X- _ I-Outcome
shown -X- _ I-Outcome
to -X- _ I-Outcome
reduce -X- _ I-Outcome
otitis -X- _ I-Outcome
media -X- _ I-Outcome
in -X- _ I-Outcome
children -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
lower -X- _ I-Outcome
respiratory -X- _ I-Outcome
tract -X- _ I-Outcome
complications -X- _ I-Outcome
, -X- _ I-Outcome
resulting -X- _ I-Outcome
in -X- _ I-Outcome
antibiotic -X- _ I-Outcome
therapy -X- _ I-Outcome
, -X- _ I-Outcome
in -X- _ I-Outcome
adults. -X- _ I-Outcome
Evidence -X- _ O
on -X- _ O
the -X- _ O
efficacy -X- _ O
of -X- _ O
NAIs -X- _ O
for -X- _ O
the -X- _ O
prevention -X- _ O
of -X- _ O
influenza-related -X- _ O
complications -X- _ O
in -X- _ O
at-risk -X- _ O
populations -X- _ O
, -X- _ O
based -X- _ O
on -X- _ O
reviews -X- _ O
of -X- _ O
data -X- _ O
from -X- _ O
randomised -X- _ O
trials -X- _ O
is -X- _ O
inconclusive. -X- _ O
However -X- _ O
, -X- _ O
observational -X- _ O
studies -X- _ O
suggest -X- _ O
that -X- _ O
in -X- _ O
hospitalised -X- _ O
patients -X- _ O
early -X- _ O
treatment -X- _ O
with -X- _ O
NAIs -X- _ B-Outcome
has -X- _ I-Outcome
been -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
reduced -X- _ I-Outcome
mortality. -X- _ I-Outcome
NAIs -X- _ B-Intervention
should -X- _ O
be -X- _ O
initiated -X- _ O
as -X- _ O
soon -X- _ O
as -X- _ O
possible -X- _ O
in -X- _ O
patients -X- _ O
at -X- _ O
high-risk -X- _ O
of -X- _ O
influenza-related -X- _ O
complications -X- _ O
, -X- _ O
with -X- _ O
suspected -X- _ O
or -X- _ O
proven -X- _ O
influenza -X- _ O
, -X- _ O
hospitalised -X- _ O
patients -X- _ O
and -X- _ O
patients -X- _ O
with -X- _ O
severe -X- _ O
or -X- _ O
progressive -X- _ O
disease. -X- _ O
NAIs -X- _ O
can -X- _ O
be -X- _ O
considered -X- _ O
in -X- _ O
previously -X- _ O
healthy -X- _ O
patients -X- _ O
when -X- _ O
therapy -X- _ O
can -X- _ O
be -X- _ O
initiated -X- _ O
within -X- _ O
48 -X- _ O
h -X- _ O
of -X- _ O
symptom -X- _ O
onset. -X- _ O
In -X- _ O
previously -X- _ O
healthy -X- _ O
patients -X- _ O
, -X- _ O
the -X- _ O
therapeutic -X- _ O
efficacy -X- _ O
of -X- _ O
oseltamivir -X- _ B-Intervention
is -X- _ O
time-dependent -X- _ O
, -X- _ O
with -X- _ O
maximal -X- _ O
benefit -X- _ O
observed -X- _ O
when -X- _ O
therapy -X- _ O
is -X- _ O
initiated -X- _ O
within -X- _ O
48 -X- _ O
h -X- _ O
of -X- _ O
symptom -X- _ O
onset. -X- _ O
However -X- _ O
, -X- _ O
several -X- _ O
observational -X- _ O
studies -X- _ O
suggest -X- _ O
therapeutic -X- _ O
benefit -X- _ O
beyond -X- _ O
48 -X- _ O
h -X- _ O
, -X- _ O
in -X- _ O
hospitalised -X- _ O
patients -X- _ O
, -X- _ O
severe -X- _ O
disease -X- _ O
, -X- _ O
and -X- _ O
patients -X- _ O
at -X- _ O
high -X- _ O
risk -X- _ O
of -X- _ O
complications -X- _ O
, -X- _ O
including -X- _ O
pregnant -X- _ O
women. -X- _ O
NAIs -X- _ O
should -X- _ O
be -X- _ O
considered -X- _ O
in -X- _ O
patients -X- _ O
at -X- _ O
high -X- _ O
risk -X- _ O
of -X- _ O
influenza-related -X- _ O
complications -X- _ O
who -X- _ O
present -X- _ O
late. -X- _ O
Further -X- _ O
studies -X- _ O
are -X- _ O
needed -X- _ O
to -X- _ O
define -X- _ O
the -X- _ O
optimal -X- _ O
timing -X- _ O
of -X- _ O
NAIs. -X- _ O
Oseltamivir-resistant -X- _ O
virus -X- _ O
has -X- _ O
been -X- _ O
widely -X- _ O
reported -X- _ O
but -X- _ O
is -X- _ O
predominantly -X- _ O
an -X- _ O
issue -X- _ O
in -X- _ O
H1N1 -X- _ O
seasonal -X- _ O
influenza. -X- _ O
Zanamivir-resistant -X- _ O
influenza -X- _ O
virus -X- _ O
is -X- _ O
rare -X- _ O
, -X- _ O
and -X- _ O
inhaled -X- _ B-Intervention
or -X- _ I-Intervention
intravenous -X- _ I-Intervention
( -X- _ I-Intervention
IV -X- _ I-Intervention
) -X- _ I-Intervention
zanamivir -X- _ I-Intervention
is -X- _ O
the -X- _ O
treatment -X- _ B-Outcome
of -X- _ I-Outcome
choice -X- _ I-Outcome
in -X- _ I-Outcome
proven -X- _ I-Outcome
or -X- _ I-Outcome
suspected -X- _ I-Outcome
oseltamivir-resistant -X- _ I-Outcome
virus. -X- _ I-Outcome
Intubated -X- _ O
patients -X- _ O
with -X- _ O
severe -X- _ O
influenza -X- _ O
can -X- _ O
be -X- _ O
treated -X- _ O
with -X- _ O
oseltamivir -X- _ B-Intervention
( -X- _ I-Intervention
suspension -X- _ I-Intervention
) -X- _ I-Intervention
administered -X- _ I-Intervention
via -X- _ I-Intervention
nasogastric -X- _ I-Intervention
tube. -X- _ I-Intervention
The -X- _ O
commercial -X- _ O
dry -X- _ O
powder -X- _ O
formulation -X- _ O
of -X- _ O
zanamivir -X- _ O
should -X- _ O
not -X- _ O
be -X- _ O
administered -X- _ O
, -X- _ O
via -X- _ O
nebulisation -X- _ O
, -X- _ O
as -X- _ O
it -X- _ O
has -X- _ O
been -X- _ O
associated -X- _ O
with -X- _ O
ventilator -X- _ O
malfunction -X- _ O
and -X- _ O
mortality. -X- _ O
In -X- _ O
intubated -X- _ O
patients -X- _ O
, -X- _ O
when -X- _ O
there -X- _ O
are -X- _ O
concerns -X- _ O
about -X- _ O
gastric -X- _ O
absorption -X- _ O
, -X- _ O
IV -X- _ B-Intervention
zanamivir -X- _ I-Intervention
should -X- _ O
be -X- _ O
obtained -X- _ O
under -X- _ O
Emergency -X- _ O
Investigational -X- _ O
New -X- _ O
Drug -X- _ O
access -X- _ O
schemes. -X- _ O
Currently -X- _ O
available -X- _ O
evidence -X- _ O
does -X- _ O
not -X- _ O
support -X- _ O
the -X- _ O
use -X- _ O
of -X- _ O
high-dose -X- _ O
or -X- _ O
extended-duration -X- _ O
oseltamivir -X- _ O
in -X- _ O
patients -X- _ O
with -X- _ O
severe -X- _ O
influenza -X- _ O
, -X- _ O
but -X- _ O
does -X- _ O
require -X- _ O
further -X- _ O
investigation. -X- _ O
Extracorporeal -X- _ B-Outcome
membrane -X- _ I-Outcome
oxygenation -X- _ I-Outcome
has -X- _ I-Outcome
not -X- _ I-Outcome
been -X- _ I-Outcome
shown -X- _ I-Outcome
to -X- _ I-Outcome
be -X- _ I-Outcome
superior -X- _ I-Outcome
to -X- _ I-Outcome
conventional -X- _ I-Outcome
management -X- _ I-Outcome
in -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
influenza- -X- _ I-Outcome
associated -X- _ I-Outcome
acute -X- _ I-Outcome
respiratory -X- _ I-Outcome
distress -X- _ I-Outcome
syndrome -X- _ I-Outcome
and -X- _ I-Outcome
should -X- _ I-Outcome
be -X- _ I-Outcome
considered -X- _ I-Outcome
as -X- _ I-Outcome
salvage -X- _ I-Outcome
therapy. -X- _ I-Outcome
Corticosteriods -X- _ I-Outcome
should -X- _ I-Outcome
not -X- _ I-Outcome
be -X- _ I-Outcome
used -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
treatment -X- _ I-Outcome
of -X- _ I-Outcome
severe -X- _ I-Outcome
influenza -X- _ I-Outcome
as -X- _ I-Outcome
this -X- _ I-Outcome
has -X- _ I-Outcome
been -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
increased -X- _ I-Outcome
risk -X- _ I-Outcome
of -X- _ I-Outcome
mortality -X- _ I-Outcome
and -X- _ I-Outcome
bacterial -X- _ I-Outcome
superinfection -X- _ I-Outcome
. -X- _ O

